• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Influence of potassium-competitive acid blocker on the gut microbiome of -negative healthy individuals.

作者信息

Otsuka Taketo, Sugimoto Mitsushige, Inoue Ryo, Ohno Masashi, Ban Hiromitsu, Nishida Atsushi, Inatomi Osamu, Takahashi Shunsuke, Naito Yuji, Andoh Akira

机构信息

Department of Medicine, Shiga University of Medical Science, Otsu, Japan.

Division of Gastrointestinal Endoscopy, Shiga University of Medical Science, Otsu, Japan.

出版信息

Gut. 2017 Sep;66(9):1723-1725. doi: 10.1136/gutjnl-2016-313312. Epub 2016 Dec 13.

DOI:10.1136/gutjnl-2016-313312
PMID:27965281
Abstract
摘要

相似文献

1
Influence of potassium-competitive acid blocker on the gut microbiome of -negative healthy individuals.钾离子竞争性酸阻滞剂对幽门螺杆菌阴性健康个体肠道微生物群的影响
Gut. 2017 Sep;66(9):1723-1725. doi: 10.1136/gutjnl-2016-313312. Epub 2016 Dec 13.
2
in human health and disease: Mechanisms for local gastric and systemic effects.在人类健康和疾病中的作用：局部胃和全身效应的机制。
World J Gastroenterol. 2018 Jul 28;24(28):3071-3089. doi: 10.3748/wjg.v24.i28.3071.
3
H. pylori and its modulation of gastrointestinal microbiota.幽门螺杆菌及其对胃肠道微生物群的调节作用。
J Dig Dis. 2015 Mar;16(3):109-17. doi: 10.1111/1751-2980.12233.
4
[Hormonal regulation of gastric secretion and Helicobacter pylori].[胃分泌的激素调节与幽门螺杆菌]
Lijec Vjesn. 2002 Sep;124 Suppl 1:13-6.
5
Helicobacter pylori and gut microbiota modulate energy homeostasis prior to inducing histopathological changes in mice.幽门螺杆菌和肠道微生物群在诱导小鼠组织病理学变化之前调节能量稳态。
Gut Microbes. 2016;7(1):48-53. doi: 10.1080/19490976.2015.1119990.
6
infection alters gut virome by expanding temperate phages linked to increased risk of colorectal cancer.感染通过扩大与结直肠癌风险增加相关的温和噬菌体来改变肠道病毒组。
Gut. 2024 Aug 8;73(9):1592-1595. doi: 10.1136/gutjnl-2023-330362.
7
Helicobacter pylori-Induced Changes in Gastric Acid Secretion and Upper Gastrointestinal Disease.幽门螺杆菌引起的胃酸分泌变化与上消化道疾病
Curr Top Microbiol Immunol. 2017;400:227-252. doi: 10.1007/978-3-319-50520-6_10.
8
The Gastric Microbiome and Its Influence on Gastric Carcinogenesis: Current Knowledge and Ongoing Research.胃微生物群及其对胃癌发生的影响：当前认知与正在进行的研究
Hematol Oncol Clin North Am. 2017 Jun;31(3):389-408. doi: 10.1016/j.hoc.2017.01.002. Epub 2017 Mar 22.
9
Impact of the Microbiota and Gastric Disease Development by Helicobacter pylori.微生物群与幽门螺杆菌引发的胃部疾病发展的关系
Curr Top Microbiol Immunol. 2017;400:253-275. doi: 10.1007/978-3-319-50520-6_11.
10
[Helicobacter pylori and gastric acid secretion].[幽门螺杆菌与胃酸分泌]
Z Gastroenterol. 1999 Feb;37(2):187-94.

引用本文的文献

1
Alterations in Gut Microbiota and Stool Properties Following Treatment with Potassium-Competitive Acid Blocker and Proton Pump Inhibitor.钾竞争性酸阻滞剂和质子泵抑制剂治疗后肠道微生物群和粪便特性的改变
Dig Dis Sci. 2025 Jul 24. doi: 10.1007/s10620-025-09228-z.
2
Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.与质子泵抑制剂相比，钾离子竞争性酸阻滞剂对接受检查点抑制剂治疗的非小细胞肺癌患者的临床结局有更多负面影响。
Int J Clin Oncol. 2025 Jun 12. doi: 10.1007/s10147-025-02805-2.
3
Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies.
胃食管反流病管理的进展：探索钾离子竞争性酸阻滞剂及新型疗法的作用
Pharmaceuticals (Basel). 2025 May 9;18(5):699. doi: 10.3390/ph18050699.
4
Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.质子泵抑制剂会降低纳武利尤单抗在不可切除的晚期或复发性胃癌中的疗效。
Immunotherapy. 2025 Apr;17(5):331-338. doi: 10.1080/1750743X.2025.2491300. Epub 2025 Apr 14.
5
Ex Vivo Analysis of the Effect of Endoscopic Premedications on the Microbiota Profile in Gastric Juice.内镜术前用药对胃液微生物群谱影响的体外分析
JGH Open. 2025 Mar 20;9(3):e70141. doi: 10.1002/jgh3.70141. eCollection 2025 Mar.
6
Proton Pump Inhibitors and Oral-Gut Microbiota: From Mechanism to Clinical Significance.质子泵抑制剂与口腔-肠道微生物群：从作用机制到临床意义
Biomedicines. 2024 Oct 7;12(10):2271. doi: 10.3390/biomedicines12102271.
7
Network Meta-Analysis of Comparing Different Dosages of Potassium-Competitive Acid Blocker With Proton-Pump Inhibitor in Acid-Related Disorders.比较不同剂量钾竞争性酸阻滞剂与质子泵抑制剂在酸相关疾病中的网状 Meta 分析。
Clin Transl Gastroenterol. 2024 Nov 1;15(11):e00776. doi: 10.14309/ctg.0000000000000776.
8
Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System.沃克帕唑相关感染：对日本药品不良反应报告和美国食品药品监督管理局不良事件报告系统的分析
Ther Adv Drug Saf. 2024 Jul 31;15:20420986241260211. doi: 10.1177/20420986241260211. eCollection 2024.
9
Changes in the Gastrointestinal Microbiota Induced by Proton Pump Inhibitors-A Review of Findings from Experimental Trials.质子泵抑制剂诱导的胃肠道微生物群变化——实验性试验结果综述
Microorganisms. 2024 May 30;12(6):1110. doi: 10.3390/microorganisms12061110.
10
Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial.利福昔明治疗慢性肠道假性梗阻患者的疗效与安全性：一项随机、双盲、安慰剂对照的II-a期探索性试验。
Biosci Microbiota Food Health. 2024;43(2):135-144. doi: 10.12938/bmfh.2023-080. Epub 2023 Dec 27.